Reversine Protocols: Practical Guide for Aurora Kinase Inhibition

What This Product Solves

Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine), supplied under SKU A3760 by APExBIO, is a small molecule designed to inhibit Aurora kinases A, B, and C. These kinases are essential for proper mitotic progression, including centrosome maturation (Aurora A) and chromosome segregation (Aurora B and C). Aberrant Aurora kinase activity is implicated in uncontrolled cancer cell proliferation, making selective inhibition a critical tool for cancer biology research. Reversine enables targeted investigation of mitotic checkpoint control, apoptosis induction in cancer cells, and modulation of the Aurora kinase signaling pathway. Its proven use in both in vitro and murine in vivo models—such as cervical cancer lines (HeLa, U14, Siha, Caski, C33A)—makes it particularly relevant for studies requiring precise manipulation of the cell cycle and assessment of cancer cell proliferation inhibition.

For researchers aiming to dissect mitotic regulatory mechanisms or develop protocols for apoptosis induction in cancer models, Reversine offers a robust, cell-permeable option. However, it should not be used for diagnostic or therapeutic applications.

Protocol Parameters

• Solubility (product-spec): DMSO (≥19.65 mg/mL), ethanol (≥6.69 mg/mL with gentle warming and ultrasonic treatment) | applicable for all in vitro and in vivo preparation steps | Ensures complete dissolution for accurate dosing; water insolubility must be considered | product information
• Storage (product-spec): -20°C (solid form) | recommended for maintaining compound stability prior to use | Minimizes degradation and preserves inhibitor activity; solutions should be freshly prepared | product information
• Working Solution and Use (workflow recommendation): Prepare immediately before experimental use; avoid long-term storage of solutions | critical for all assay types, especially cell-based and in vivo studies | Reversine solutions are prone to degradation; prompt use maximizes reproducibility | workflow recommendation
• Concentration Range (workflow recommendation): Typical in vitro working concentrations: 0.1–10 μM (must optimize per cell line and endpoint) | for cancer cell proliferation inhibition, apoptosis induction, or cell cycle assays | Empirical titration required to balance efficacy and cytotoxicity | workflow recommendation
• Vehicle Control (workflow recommendation): Match final DMSO or ethanol concentration to that used for Reversine-treated samples, not exceeding 0.1–0.5% (v/v) in cell culture | required for all cell-based assays | Controls for solvent effects on cell viability and assay readouts | workflow recommendation

Workflow Setup and QC Checklist

• Compound Handling: Upon receipt, verify product integrity and transfer immediately to -20°C storage. Minimize freeze-thaw cycles by aliquoting solid material as required.
• Solution Preparation: Dissolve Reversine in DMSO or ethanol, using gentle warming and brief sonication for ethanol. Confirm full dissolution visually and by absence of particulates after mixing.
• Assay Design: Establish dose-response curves in preliminary assays using a range from 0.1 μM up to 10 μM, with vehicle-only controls in parallel. Adjust concentrations based on observed effects on cell cycle progression or apoptosis induction in cancer cells.
• Quality Control: Routinely verify the absence of precipitation in working solutions. Discard any aliquots showing turbidity or color change.
• Documentation: Record lot number, preparation date, and solvent concentrations for each experiment. Include these details in all downstream data reporting for reproducibility.

Common Failure Modes and Fixes

• Poor Solubility or Precipitation: If undissolved material persists, increase mixing time or apply gentle heat (avoid exceeding 37°C). For ethanol, ultrasonication may be necessary. Always pre-filter solutions through a 0.22 μm syringe filter if sterility is required.
• Loss of Activity Due to Degradation: Prepare fresh solutions immediately before use. Discard solutions stored for more than a few hours, as prolonged storage (even at 4°C) can reduce inhibitor effectiveness.
• Inconsistent Biological Response: Ensure accurate pipetting and homogeneous mixing. Confirm that final DMSO or ethanol concentration is matched across all samples. If experimental variability persists, validate cell line sensitivity and examine potential cross-contamination or mycoplasma infection.
• Cytotoxicity in Control Samples: If vehicle controls display unexpected cytotoxicity, reduce solvent concentration or switch to DMSO if ethanol is problematic for the cell type.

Scope and Limitations

Reversine is validated for use in cancer cell proliferation inhibition, apoptosis induction in cancer cells, and modulation of the Aurora kinase signaling pathway in both in vitro and murine in vivo research settings. Its application is best suited to mechanistic studies of mitotic regulation, especially in cancer biology and cell cycle research. However, Reversine is not intended for diagnostic or therapeutic purposes, and its water insolubility constrains usage to DMSO or ethanol-based formulations. Long-term storage of solutions is not recommended, and protocol optimization is required for each experimental system. No direct evidence supports its use beyond the cell types and models described in the product dossier. Any off-target or cross-kinase effects should be empirically evaluated.

Researchers seeking advanced workflows and troubleshooting strategies may find further procedural guidance in the internal article "Reversine: Aurora Kinase Inhibitor for Cancer Research Workflows", which details setup for high-throughput screening and apoptosis assays. For a broader context on precision mitotic regulation in complex models, see "Reversine: Precision Aurora Kinase Inhibition in Gastruloid and Cancer Models".

Conclusion

Reversine provides a robust, reproducible tool for researchers investigating Aurora kinase-dependent mitotic processes and cancer cell cycle regulation. By adhering to best practices in compound handling, solution preparation, and assay design, users can maximize the consistency and interpretability of their results. For additional product details and technical specifications, refer to Reversine at APExBIO.